Dr. Jim Phelps discusses diagnosing bipolar disorder within a mood spectrum and the challenges of transitioning from a categorical to dimensional approach. The podcast explores treatment considerations, risks and benefits of prescribing an SRI, alternative mood stabilizers, and essential diagnostic tools such as the bipolarity index and mood check questionnaire.

In this podcast, Dr. Schenck discusses zolpidem-induced sleeping disorder and eating disorder. Listen and find out important tips and considerations, such as this being more common in females, alerting bed partners, being careful with zolpidem doses over 10 mg, and more. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep-Related Eating Disorder Zolpidem-Induced Sleepwalking and SRED

Cariprazine may be a good option for pediatric patients with schizophrenia and bipolar I disorder. Listen as Dr. Rosenberg summarizes study findings, which may broaden your options with children and adolescents. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 11 Safety and Tolerability of Cariprazine in Pediatric Patients

This podcast explores medication associated with sleepwalking and sleep driving, as well as recommendations for clinicians when prescribing them to patients. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep-Related Eating Disorder Medication-Induced SRED, Sleepwalking, and Sleepdriving  

In this episode, we explore whether the olanzapine–samidorphan combination helps with psychosis while halting weight gain. We also look into the cost vs benefit of the combination as well as the metabolic side effects. Faculty: James Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 51 Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis

Can melatonin reduce the risk of suicidality, bodily injuries, falls, and accidents in children and adolescents? In this episode, we explore a study that delves into this question. Discover how sleep disturbances impact young individuals' health, development, cognitive skills, emotional regulation, and behavior. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 11 Melatonin Use and the Risk of Self-Harm and Unintentional Injuries in Youth

Discover the intricacies of sleep-related eating disorder (SRED), including its diagnostic criteria, association with other sleep disorders like sleepwalking and restless leg syndrome, and triggers such as certain medications. Learn about the behaviors associated with SRED, its impact on sleep and health, and the significance of accurate diagnosis and treatment.

This episode explores the controversial role of pimavanserin in treating psychosis in Parkinson's disease. How does it compare with quetiapine or clozapine? Sneak peek: All of these medications are effective, yet none distinctly surpasses the others. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 51 Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis

Explore the challenges and updates in treating pediatric bipolar disorder, including the use of FDA-approved medications since 2005. Learn about different treatment approaches, the importance of close monitoring, and comprehensive lifestyle changes. Discover the advantages and limitations of using lithium and second-generation anti-psychotics. Explore the best-practice treatment algorithms, including FDA-approved medications and non-medication options like CBT, while balancing efficacy and side effects.

Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests.  Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 49 Effect of Pharmacogenomic Testing for Drug–Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial